BiotechTube
Axela Biosciences

Axela Biosciences

Toronto, United States· Est.
axelabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11.2M

Overview

Axela Biosciences is a privately held CRO that provides sophisticated bioanalytical services to accelerate drug discovery and development. Leveraging a suite of cutting-edge platforms like SIMOA, NanoString GeoMx, and multiplex Luminex assays, the company focuses on generating rich, high-quality data from small sample volumes for clients in oncology, autoimmunity, and other therapeutic areas. With a team experienced from top institutions and biopharma companies, Axela positions itself as a strategic partner for R&D, offering services from early discovery through translational development.

OncologyAutoimmune DiseasesInflammation

Technology Platform

Integrated suite of ultra-sensitive and multiplex bioanalytical platforms including SIMOA (single molecule array), NanoString nCounter & GeoMx DSP (spatial biology), Luminex, advanced flow/mass cytometry, automated western blot, protein microarrays, and live-cell analysis systems.

Funding History

4
Total raised:$11.2M
Series A$5M
Grant$1.2M
Series A$5M
SeedUndisclosed

Opportunities

Growing demand for complex, multi-omic data from limited samples in precision medicine and translational research presents a significant opportunity.
Expansion of service offerings in high-growth areas like spatial biology and targeted protein degradation screening can further differentiate the company.
Forming strategic R&D collaborations with biotech and pharma partners can lead to deeper, more sustainable relationships beyond transactional services.

Risk Factors

Revenue is vulnerable to cyclical swings in biopharma R&D spending and project-based client demand.
The company operates in a highly competitive CRO market against both large global players and niche specialists.
Maintaining a technological edge requires continuous, capital-intensive investment in rapidly evolving instrumentation and assay platforms.

Competitive Landscape

Axela competes in a fragmented CRO market, facing competition from large, full-service CROs (e.g., LabCorp, IQVIA) that offer broad capabilities and global scale, as well as from numerous niche specialty labs focusing on specific technologies like flow cytometry, genomics, or proteomics. Its differentiation lies in integrating multiple high-end, sensitive platforms to offer a comprehensive, sample-sparing service package from a single provider.

More companies in Diagnostics & Precision Medicine →More companies in United States →